Sirio Pharma Co.Ltd(300791) 2020 Annual Report
Securities code: Sirio Pharma Co.Ltd(300791) securities abbreviation: Sirio Pharma Co.Ltd(300791) announcement Code: 2022015 securities code: 123113 securities abbreviation: xianle convertible bonds
SIRIO PHARMA CO., LTD.
Annual report for 2021
Lead nutrition technology and add value to health
Disclosure date: April 12, 2022
Section I important tips, contents and definitions
1. The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
2. Lin Peiqing, the person in charge of the company, Zheng Liqun, the person in charge of accounting, and Xie Wanrong, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this annual report.
3. All directors have attended the meeting of the board of directors to consider this report.
4. The development strategy and future forward-looking statements involved in this report do not constitute the company’s substantive commitment to investors. Investors and relevant persons should maintain sufficient risk awareness and understand the differences between plans, forecasts and commitments.
5. The company shall comply with the disclosure requirements of Shenzhen stock exchange industry information disclosure guidelines No. 14 – listed companies engaged in food and wine manufacturing related businesses
6. The company invites investors to carefully read the full text of this annual report and pay special attention to the following risk factors:
(1) Covid-19 pneumonia epidemic risk
The repeated outbreak of covid-19 pneumonia outside China may have a certain impact on the company’s domestic and foreign production and operation activities and export business logistics. In this regard, the company and its subsidiaries set up emergency response teams to closely track and evaluate the progress of the epidemic, formulate response plans in advance and reduce possible risks.
(2) Product quality management risk
There are many kinds of nutritious and healthy foods, the product renewal speed is faster and faster, and the new food safety standards are constantly issued, which puts higher and higher requirements on the food quality and safety of enterprises. If the company makes quality management mistakes in raw material procurement, production, storage or transportation, it may produce product safety risks, which will affect the company’s reputation and product sales. The company has 20 years of experience in R & D and production of nutritious and healthy food, and always puts product quality and safety first. The company has accumulated a quality management and control team with rich professional experience and outstanding professional ability. In addition to establishing various quality control systems and processes, the quality control team also goes deep into material management, product production, product packaging, finished product and semi-finished product storage and other links in real time to implement and follow up the quality control requirements on site. At the same time, the company continues to strengthen the quality management concept of full participation and improve the quality management awareness of all employees. In addition, the company has established an inspection center recognized by CNAs. The inspection center is equipped with precision testing equipment and professional testing personnel, with perfect quality testing and control ability, which can effectively help the company manage and control product quality risks. In addition, the company has introduced advanced quality management electronic system internally, continuously optimized quality management process, and continuously identified, avoided and actively controlled quality risks with the help of irregular customer audit and quality management system audit, so as to control the risks in the embryonic stage.
(3) Industry policy risk
In addition to the supervision of basic laws, regulations and industry normative documents such as the food safety law, the regulations on the implementation of the food safety law, the advertising law, the administrative measures for the registration and filing of health food, the guidelines for the filing of health food (for Trial Implementation), the national standard for food safety – health food, due to the characteristics of the industry, the nutrition and health food industry also needs to comply with the policies and regulations issued by the regulatory authorities from time to time. In recent years, with the increasing attention of the state to food safety, the revision frequency of existing laws and regulations and the introduction speed of new laws and regulations have been significantly accelerated. At the same time, the regulatory policies of the regulatory authorities for the nutritional and healthy food industry are becoming more and more strict, the regulatory measures are becoming more and more detailed, and the regulatory strength is correspondingly higher and higher. This puts forward higher requirements for the company’s production and operation. If the company fails to timely adjust and effectively implement the enterprise development strategy and internal management system, it will face certain business risks. In this regard, the company has a professional regulation department to actively participate in the formulation and revision of industrial laws, regulations and standards, regularly study and study new policies and regulations, formulate internal control standards and measures synchronized with policies and regulations, implement the requirements of laws and regulations into the daily operation process through internal processes, control the daily operation of the company in real time, and help the company fully comply with the latest industrial policies and regulations.
(4) Risk of intensified market competition
With the continuous improvement of national and people’s awareness of health, the nutritional and healthy food industry has been recognized by people more and more. As a sunrise industry encouraged by the state, the nutrition and health food industry has grown rapidly in recent years, with the continuous participation of various business entities. The number of enterprises engaged in the production and operation of nutrition and health food has increased rapidly, including many cross industry entrants, which makes the industry competitive and complex. If the company’s investment in business development, supply chain management, R & D and other aspects is wrong or the efficiency is reduced, it will affect the existing advantages of the company, and then cause customers to change suppliers and affect the performance of the company. In this regard, the company carried out the transformation and upgrading of the organizational structure, strengthened product innovation on the premise of in-depth insight into the market demand, created a management model with the market as the core, focused internal resources on the front end, and repositioned all departments through the division of small business units, released their potential and stimulated the vitality of the organization. According to the channel strategy of multi-channel coverage, quickly respond to market demand and maintain competitive advantage.
(5) Exchange rate fluctuation risk
The company has a lot of overseas export business, mainly in the Americas and Europe. Since the reform of China’s exchange rate system in 2005, the exchange rate of RMB against other currencies has fluctuated significantly. The sharp fluctuation of exchange rate will have an impact on the company’s export business. If the exchange loss is greater than the exchange gain, it will have an adverse impact on the company’s operating performance. In this regard, the company will control the risks caused by exchange rate fluctuations by signing agreements with banks to lock the exchange rate and adjust foreign exchange exposure according to the actual situation.
(6) Goodwill impairment risk
As the company’s acquisition of Germany ayanda in December 2016 is a business combination not under the same control, according to the accounting standards for business enterprises, the difference between the merger cost and the fair value of the identifiable net assets of the acquiree obtained in the merger shall be recognized as goodwill.
Such goodwill is not amortized, but needs to be tested for impairment at the end of each fiscal year in the future. At the end of the reporting period, the book value of the company’s goodwill was 158589600 yuan, accounting for 6.23% of the owner’s equity attributable to the parent company at the end of the reporting period. If Germany’s ayanda can not achieve better income in its future operation, the goodwill formed by the acquisition of Germany’s ayanda will be subject to impairment risk, which will have an adverse impact on the company’s operating performance.
7. The company’s profit distribution plan approved by the board of directors is: take 180169870 shares as the base, distribute cash dividends of 4 yuan (including tax) to all shareholders for every 10 shares, do not give bonus shares, and do not use the accumulation fund to increase the share capital.
catalogue
Section I important tips, contents and definitions Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section IV corporate governance 39 Section V environmental and social responsibility Section VI important matters Section 7 share changes and shareholders 77 Section VIII information related to bonds 85 section IX Financial Report eighty-eight
Directory of documents for future reference
1. The 2021 annual report with the signature of the company’s legal representative and the seal of the company;
2. The text of the financial report containing the signatures and seals of the person in charge of the unit, the person in charge of accounting work and the person in charge of the accounting institution (the person in charge of Accounting);
3. Originals of all company documents and announcements publicly disclosed during the reporting period;
4. Other relevant information.
Place of preparation of the above documents for future reference: Office of the board of directors of the company
interpretation
Explanatory item refers to the explanatory content
Sirio Pharma Co.Ltd(300791) , the company and the company refer to Sirio Pharma Co.Ltd(300791)
Xianle Pharmaceutical Co., Ltd. refers to Guangdong xianle Pharmaceutical Co., Ltd., which is the predecessor of Sirio Pharma Co.Ltd(300791) company
Guangdong Guanghui refers to Guangdong Guanghui Investment Co., Ltd., which is the controlling shareholder of the company
Anhui xianle refers to Sirio Pharma Co.Ltd(300791) Technology (Anhui) Co., Ltd., which is a wholly-owned subsidiary of the company
Ayanda refers to ayanda GmbH, a wholly-owned subsidiary of the company
Weilewei refers to weilewei Health Industry Co., Ltd., which is a wholly-owned subsidiary of the company
Heshi biotechnology refers to Guangdong Heshi Biotechnology Co., Ltd., which is a wholly-owned subsidiary of the company
Xianle biotechnology refers to xianle (Shanghai) Life Technology Co., Ltd., which is a wholly-owned subsidiary of the company
CSRC and CSRC refer to China Securities Regulatory Commission
Shenzhen stock exchange refers to Shenzhen Stock Exchange
Company Law refers to the company law of the people’s Republic of China
Securities Law refers to the securities law of the people’s Republic of China
Yuan and 10000 yuan refer to RMB yuan and 10000 yuan
Reporting period and current year refer to the period from January 1, 2021 to December 31, 2021
The same period of last year refers to the period from January 1, 2020 to December 31, 2020
Cninfo.com refers to http://www.cn.info.com.cn.
Nutritious and healthy food refers to health food, nutritious functional food, special dietary food and nutritious fortified food.
Food claimed to have specific health care functions or for the purpose of supplementing vitamins and minerals
Health food refers to food. That is, it is suitable for specific people to eat, has the function of regulating the body, is not for the purpose of treating diseases, and does not produce any acute, subacute or chronic harm to the human body.
Nutritional functional food refers to the food added with ingredients with nutritional value or beneficial to the normal physiological function of human body.
In order to meet special physical or physiological conditions and / or meet the special dietary needs of diseases and disorders, food refers to food specially processed or formulated. The nutrients and
(or) the content of other nutrients is significantly different from that of comparable ordinary food.
Nutritional fortified food refers to the food that adds natural or synthetic nutrients and other nutrients to increase nutrients (value).
CSI PENGYUAN refers to CSI PENGYUAN credit evaluation Co., Ltd
Section II Company Profile and main financial indicators
1、 Company information
Stock abbreviation Sirio Pharma Co.Ltd(300791) stock code Sirio Pharma Co.Ltd(300791)
Chinese name of the company Sirio Pharma Co.Ltd(300791) branch
